头孢他啶-阿维巴坦对从囊性纤维化患者呼吸道样本中分离出的多重耐药菌的抗菌活性趋势。 - Suppr

Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.

作者信息

Farfour Eric, Trochu Erwan, Devin Clotilde, Cardot Martin Emilie, Limousin Lucie, Roux Antoine, Picard Clément, Jolly Emilie, Vasse Marc, Lesprit Philippe

机构信息

Service de Biologie Clinique, Hôpital Foch, Suresnes, France.

Service de Pneumologie, Hôpital Foch, Suresnes, France.

出版信息

Transpl Infect Dis. 2018 Oct;20(5):e12955. doi: 10.1111/tid.12955. Epub 2018 Jun 25.

DOI:10.1111/tid.12955

PMID:29896802

Abstract

摘要

相似文献

Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.

Transpl Infect Dis. 2018 Oct;20(5):e12955. doi: 10.1111/tid.12955. Epub 2018 Jun 25.

In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.

J Med Microbiol. 2018 Sep;67(9):1217-1220. doi: 10.1099/jmm.0.000801. Epub 2018 Jul 17.

Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.

J Antimicrob Chemother. 2019 May 1;74(5):1425-1429. doi: 10.1093/jac/dky558.

Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam.

Infection. 2019 Apr;47(2):289-292. doi: 10.1007/s15010-018-1261-y. Epub 2018 Dec 19.

Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.

J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204.

"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Complex and Cystic Fibrosis Isolates.

J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00181-19. Print 2019 Aug.

Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for reacutization.

J Chemother. 2019 Nov-Dec;31(7-8):436-438. doi: 10.1080/1120009X.2019.1671654. Epub 2019 Oct 4.

In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.

J Antimicrob Chemother. 2019 Feb 1;74(2):380-386. doi: 10.1093/jac/dky425.

引用本文的文献

Antimicrobial Treatment Strategies for : A Focus on Novel Therapies.

Antibiotics (Basel). 2021 Oct 9;10(10):1226. doi: 10.3390/antibiotics10101226.

Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0133221. doi: 10.1128/AAC.01332-21. Epub 2021 Aug 9.

Advances in the Microbiology of Stenotrophomonas maltophilia.

Clin Microbiol Rev. 2021 Jun 16;34(3):e0003019. doi: 10.1128/CMR.00030-19. Epub 2021 May 26.

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.

BMC Microbiol. 2021 Feb 22;21(1):60. doi: 10.1186/s12866-021-02108-2.

New Therapeutic Approaches in Cystic Fibrosis.

Turk J Pharm Sci. 2020 Dec 23;17(6):686-697. doi: 10.4274/tjps.galenos.2020.76401.

Infections and Treatment Options.

Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01025-20.

"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Complex and Cystic Fibrosis Isolates.

J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00181-19. Print 2019 Aug.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献